Table 3.
Prevalence of lipid abnormalities between baseline data with different follow-up periods.
| Baseline (n = 546) | At 6 months (n = 519) | At 12 months (n = 441) | At 18 months (n = 313) | At 24 months (n = 200) | At 30 months (n = 142) | |
|---|---|---|---|---|---|---|
| A. TC, ≥ 5.18 mmol/l; ≥ 200 mg/dl | ||||||
| NNRTIs Group | 29 (7.7) | 30 (8.8) | 36 (12.0) | 30 (13.5) | 24 (16.8) | 11 (10.3) |
| INSTIs Group | 15 (8.9) | 26 (14.4) | 23 (16.4) | 10 (11.0) | 9 (15.8) | 8 (22.9) |
| P-value | 0.639 | 0.051 | 0.199 | 0.544 | 0.864 | 0.083 |
| All patients | 44 (8.1) | 56 (10.8) | 59 (13.4) | 40 (12.8) | 33 (16.5) | 19 (13.4) |
| B. TG, ≥ 1.70 mmol/l; ≥ 150 mg/dl | ||||||
| Baseline | At 6 months | At 12 months | At 18 months | At 24 months | At 30 months | |
| NNRTIs Group | 76 (20.2) | 86 (25.4) | 84 (27.9) | 51 (23.0) | 44 (30.8) | 21(19.6) |
| INSTIs Group | 43 (25.4) | 63 (35.0) | 44 (31.4) | 34 (37.4) | 22 (38.6) | 13(37.1) |
| P-value | 0.167 | 0.021 | 0.448 | 0.009 | 0.288 | 0.035 |
| All patients | 119 (21.8) | 149 (28.7) | 128 (29.0) | 85 (27.2) | 66 (33.0) | 34(23.9) |
| C. HDL-C, ≤ 1.04 mmol/l; < 40 mg/dl | ||||||
| Baseline | At 6 months | At 12 months | At 18 months | At 24 months | At 30 months | |
| NNRTIs Group | 240 (63.7) | 170 (50.1) | 133 (44.2) | 107 (48.2) | 60 (42.0) | 46 (43.0) |
| INSTIs Group | 108 (63.9) | 99 (55.0) | 69 (49.3) | 45 (49.5) | 27 (47.4) | 14 (40.0) |
| P-value | 0.956 | 0.292 | 0.317 | 0.840 | 0.486 | 0.756 |
| All patients | 348 (63.7) | 269 (51.8) | 202 (45.8) | 152 (48.6) | 87 (43.5) | 60 (42.3) |
| D. LDL-C, ≥ 3.37 mmol/l; ≥ 130 mg/dl | ||||||
| Baseline | At 6 months | At 12 months | At 18 months | At 24 months | At 30 months | |
| NNRTIs Group | 37 (9.8) | 27 (8.0) | 33 (11.0) | 32 (14.4) | 21 (14.7) | 11 (10.3) |
| INSTIs Group | 19 (11.2) | 22 (12.2) | 15 (10.7) | 16 (17.6) | 11 (19.3) | 10 (28.6) |
| P-value | 0.611 | 0.114 | 0.938 | 0.480 | 0.422 | 0.008 |
| All patients | 56 (10.3) | 49 (9.4) | 48 (10.9) | 48 (15.3) | 32 (16.0) | 21 (14.8) |
| E. Lp(a), ≥30 mg/dl | ||||||
| Baseline | At 6 months | At 12 months | At 18 months | At 24 months | At 30 months | |
| NNRTIs Group | 40 (10.6) | 41 (12.1) | 30 (10.0) | 32 (14.4) | 14 (12.1) | 11 (10.3) |
| INSTIs Group | 14 (8.3) | 20 (11.1) | 11 (7.9) | 9 (10.0) | 6 (11.3) | 4 (11.4) |
| P-value | 0.400 | 0.741 | 0.478 | 0.296 | 0.889 | 0.849 |
| All patients | 54 (9.9) | 61 (11.8) | 41 (9.4) | 41 (13.1) | 20 (11.8) | 15 (10.6) |
| F. TC/HDL-C, >5 | ||||||
| Baseline | At 6 months | At 12 months | At 18 months | At 24 months | At 30 months | |
| NNRTIs Group | 64 (17.0) | 42 (12.4) | 29 (9.6) | 29 (13.1) | 16 (11.2) | 14 (13.1) |
| INSTIs Group | 37 (21.9) | 40 (22.2) | 29 (20.7) | 21 (23.1) | 9 (15.8) | 11 (31.4) |
| P-value | 0.171 | 0.003 | 0.001 | 0.028 | 0.374 | 0.013 |
| All patients | 101 (18.5) | 82 (15.8) | 58 (13.2) | 50 (16.0) | 25 (12.5) | 25 (17.6) |
NA = not available. p values < 0.05 are written in italics.
Values shown are (%). p values were calculated by Chi-squared test, Fisher’s exact test, as appropriate.
ART, antiretroviral therapy; %, percentage, NNRTIs, non-nucleoside reverse transcriptase inhibitor; INSTIs, integrase strand transfer inhibitors; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; Lp(a), Lipoprotein(a); TC/HDL-C ratio, total cholesterol/high-density lipoprotein-cholesterol ratio.